SAN FRANCISCO--(BUSINESS WIRE)--Headlands Research, a leading multinational network of clinical trial sites, today announced that the company’s Board of Directors has appointed Kyle Burtnett as Chief Executive Officer (CEO), effective July 3. Kyle succeeds interim CEO Cathy Collins, who will remain closely involved with Headlands as a board member and advisor to the CEO.
“Headlands Research is in a phase of substantial growth, expanding its therapeutic and geographic reach and providing access to clinical research at 15 sites, serving a more diverse, representative population. I am excited to work alongside the talented team at Headlands Research as we continue growing our clinical footprint, driving medical innovation by supporting our clients, and improving the lives of patients,” said Kyle Burtnett, CEO of Headlands Research.
Kyle has extensive experience scaling and managing organizations across multiple health care sectors. Prior to joining Headlands, Kyle served as President of GI Alliance, the nation’s premier network of gastroenterology specialists, with over 800 physicians across 15 states. At GI Alliance, Kyle played a key role in supporting the organization’s rapid growth and ensuring a highly successful physician-led recapitalization of the business at a $2.2 billion valuation. Kyle also worked directly with GI Alliance’s industry-leading GI clinical research function with more than 20 sites. Prior to GI Alliance, Kyle spent 17 years at Tenet Healthcare, where he held multiple executive leadership roles, including COO & Interim CEO of Conifer Health Solutions and CEO of Tenet’s Outpatient Services Division.
“Headlands has experienced substantial growth over the past several years and has never been in a stronger position, with industry-leading clinical and corporate infrastructure and a growing network of high-performance and therapeutically-diversified sites. We look forward to supporting Kyle in taking the company to the next level and would also like to thank Cathy for her leadership as interim CEO,” said Ali Satvat, Partner at KKR and Global Head of KKR Health Care Strategic Growth.
“Kyle brings a wealth of relevant experience and strategic vision to guide Headlands. We are confident that his unique background of managing operationally-sophisticated multi-site health care organizations, interfacing closely with physicians and patients, executing on meaningful M&A, and overseeing best-in-class clinical research programs will help position Headlands for continued success,” said Anuv Ratan, Director at KKR.
Headlands Research recently launched one new clinical research site and acquired two additional established sites, including Headlands Research Detroit, which serves multiple therapeutic areas, including Alzheimer’s disease and vaccines; Headlands Research Eastern Massachusetts, which specializes in neurodegenerative diseases such as Alzheimer’s disease; and Clinvest Research, which specializes in chronic diseases including migraine and arthritis.
About Headlands Research
Headlands Research is a multinational integrated clinical trial site organization with a mission to improve lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.